Pharmaxis concludes Brochitol trial
Friday, 13 June, 2008
Pharmaxis (ASX:PXS) has completed a Phase III clinical trial of its Bronchitol inhalant spray for bronchiectasis.
The 12-month trial was an open label extension to an earlier efficacy trial and was designed to determine the adverse event profile of Bronchitol following prolonged use.
Bronchiectasis is an incurable and chronic lung condition which causes excessive mucus to build up in the lungs, making breathing difficult.
Pharmaxis intends to file a marketing application for Bronchitol after the results are published in July.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
